Anti-Chol-1 Antigen, GQ1bα, Antibodies Are Associated with Alzheimer’s Disease
暂无分享,去创建一个
[1] O. Andersen,et al. Myelin glycosphingolipid immunoreactivity and CSF levels in multiple sclerosis , 2012, Acta neurologica Scandinavica.
[2] T. Kanda,et al. Establishment of a new conditionally immortalized human brain microvascular endothelial cell line retaining an in vivo blood–brain barrier function , 2010, Journal of cellular physiology.
[3] J. Buccafusco,et al. Ganglioside metabolism in a transgenic mouse model of Alzheimer's disease: expression of Chol-1α antigens in the brain , 2010, ASN neuro.
[4] T. Miyatake,et al. Role of proteoglycans and glycosaminoglycans in the pathogenesis of Alzheimer's disease and related disorders: Amyloidogenesis and therapeutic strategies—A review , 2010, Journal of neuroscience research.
[5] Marko Vuskovic,et al. Anti-carbohydrate antibodies of normal sera: findings, surprises and challenges. , 2009, Molecular immunology.
[6] Bruce D. Trapp,et al. Axonal degeneration and progressive neurologic disability in multiple sclerosis , 2009, Neurotoxicity Research.
[7] B. Kálmán,et al. Autoantibodies and neurodegeneration in multiple sclerosis , 2008, Laboratory Investigation.
[8] M. P. McDonald,et al. Role of ganglioside metabolism in the pathogenesis of Alzheimer's disease--a review. , 2008, Journal of lipid research.
[9] J. Geiger,et al. Caffeine blocks disruption of blood brain barrier in a rabbit model of Alzheimer's disease , 2008, Journal of Neuroinflammation.
[10] Stavros J. Baloyannis,et al. Antibodies Against GM1 in Demented Patients , 2008, American journal of Alzheimer's disease and other dementias.
[11] T. Ariga,et al. Developmental changes of glycosphingolipids and expression of glycogenes in mouse brains , 2007, Journal of neurochemistry.
[12] M. D'Andrea,et al. Aβ peptides can enter the brain through a defective blood–brain barrier and bind selectively to neurons , 2007, Brain Research.
[13] P. Carvey,et al. Blood–Brain Barrier Pathology in Alzheimer's and Parkinson's Disease: Implications for Drug Therapy , 2007, Cell transplantation.
[14] S. Mori,et al. Passive Immunization with Anti-Ganglioside Antibodies Directly Inhibits Axon Regeneration in an Animal Model , 2007, The Journal of Neuroscience.
[15] R. Yu,et al. Ganglioside Molecular Mimicry and Its Pathological Roles in Guillain-Barré Syndrome and Related Diseases , 2006, Infection and Immunity.
[16] M. Acler,et al. Anti-GD2-like IgM autoreactivity in multiple sclerosis patients , 2006, Multiple sclerosis.
[17] T. S. Saravanan,et al. Human Antiganglioside Autoantibodies: Validation of ELISA , 2005, Annals of the New York Academy of Sciences.
[18] J. Raphaël,et al. [Guillain-Barré syndrome]. , 2005, La Revue du praticien.
[19] K. Majtényi,et al. Serum IgG and IgM ganglioside GM1 antibodies in patients with multiple sclerosis. , 2004, Ideggyogyaszati szemle.
[20] B. Winblad,et al. Evidence for the presence of antibodies to cholinergic neurons in the serum of patients with Alzheimer's disease , 1987, Journal of Neurology.
[21] S. Cook,et al. Antibodies to sulfatide in cerebrospinal fluid of patients with multiple sclerosis , 2003, Journal of Neuroimmunology.
[22] R. Nussbaum,et al. Alzheimer's disease and Parkinson's disease. , 2003, The New England journal of medicine.
[23] M. Pender,et al. Increased circulating T cell reactivity to GM3 and GQ1b gangliosides in primary progressive multiple sclerosis , 2003, Journal of Clinical Neuroscience.
[24] M Zappia,et al. Anti‐GM1 ganglioside antibodies in Parkinson's disease , 2002, Acta neurologica Scandinavica.
[25] S. McQuaid,et al. Abnormal Endothelial Tight Junctions in Active Lesions and Normal‐appearing White Matter in Multiple Sclerosis , 2002, Brain pathology.
[26] T. Kanda,et al. Anti-GM1 antibody facilitates leakage in an in vitro blood–nerve barrier model , 2000, Neurology.
[27] N. Yuki,et al. Isolated absence of F waves and proximal axonal dysfunction in Guillain-Barré syndrome with antiganglioside antibodies , 2000, Journal of neurology, neurosurgery, and psychiatry.
[28] A. Mosek,et al. Dementia and Antiphospholipid Antibodies , 2000, Dementia and Geriatric Cognitive Disorders.
[29] F. Lolli,et al. Multiple sclerosis is associated with enhanced B cell responses to the ganglioside GD I a , 1999, Multiple sclerosis.
[30] M. Pender,et al. Increased circulating antiganglioside antibodies in primary and secondary progressive multiple sclerosis , 1998, Annals of neurology.
[31] G. Nores,et al. Anti‐GM1 ganglioside igm‐antibodies present in human plasma: Affinity and biological activity changes in a patient with neuropathy , 1998, Journal of neuroscience research.
[32] N. Yuki,et al. Antibodies to fucogangliosides in neurological diseases , 1997, Journal of the Neurological Sciences.
[33] X. Montalban,et al. Different antiganglioside antibody pattern between relapsing‐remitting and progressive multiple sclerosis , 1996, Acta neurologica Scandinavica.
[34] A. Batra,et al. Autoantibody reactivity in serum of patients with alzheimer's disease and other age-related dementias , 1996, Psychiatry Research.
[35] H. Wiegandt,et al. Characterization of anti-ganglioside antibodies present in normal human plasma , 1994, Journal of Neuroimmunology.
[36] R. Yu,et al. Development regulation of ganglioside metabolism. , 1994, Progress in brain research.
[37] R. A. Klein,et al. O-acetylated gangliosides in bovine buttermilk. Characterization of 7-O-acetyl, 9-O-acetyl, and 7,9-di-O-acetyl GD3. , 1992, The Journal of biological chemistry.
[38] V. P. Whittaker,et al. Structural characterization of a novel cholinergic neuron-specific ganglioside in bovine brain. , 1992, The Journal of biological chemistry.
[39] V. P. Whittaker,et al. A trisialoganglioside containing a sialyl α2-6 N-acetylgalactosamine residue is a cholinergic-specific antigen, chol-1α , 1992 .
[40] V. P. Whittaker,et al. A trisialoganglioside containing a sialyl alpha 2-6 N-acetylgalactosamine residue is a cholinergic-specific antigen, Chol-1 alpha. , 1992, Journal of biochemistry.
[41] E. Derrington,et al. The developmental expression of the cholinergic-specific antigen Chol-1 in the central and peripheral nervous system of the rat. , 1990, Brain research. Developmental brain research.
[42] D. Michaelson,et al. Antibodies to Cholinergic Neurons in Alzheimer's Disease , 1988, Journal of neurochemistry.
[43] D. Michaelson,et al. Antibodies to ganglioside GM1 in patients with Alzheimer's disease , 1988, Neuroscience Letters.
[44] S. Kusunoki,et al. Subcellular Localization of Sulfated Glucuronic Acid‐Containing Glycolipids Reacting with Anti‐Myelin‐Associated Glycoprotein Antibody , 1987, Journal of neurochemistry.
[45] R. Yu,et al. Isolation and characterization of ganglioside GM1b from normal human brain. , 1987, Journal of lipid research.
[46] N. Kasai,et al. Anti-glycolipid antibodies and their immune complexes in multiple sclerosis , 1986, Journal of the Neurological Sciences.
[47] N. Latov,et al. The neuropathy of plasma cell dyscrasia , 1985, Neurology.
[48] T. Miyatake,et al. Isolation and characterization of a novel disialoganglioside from bovine adrenal medulla. , 1984, Archives of biochemistry and biophysics.
[49] T. Yasuda,et al. Activation of the alternative complement pathway by natural antibody to glycolipids in guinea-pig serum. , 1983, Immunology.
[50] R. Yu,et al. Isolation and characterization of a novel trisialoganglioside, GT1a, from human brain. , 1977, The Journal of biological chemistry.